LIFECORE BIOMEDICAL, INC. DE (LFCR): Nasdaq/NYSE listing notice — Lifecore Biomedical receives Nasdaq notice for delayed Q2 FY2023 10-Q filing

LIFECORE BIOMEDICAL, INC. DE

Nasdaq notified Lifecore on Jan 11, 2023 of non-compliance with Listing Rule 5250(c)(1) due to late 10-Q.
Company has 60 days (until Mar 12, 2023) to submit a plan to regain compliance.
If plan accepted, Nasdaq may grant up to 180 days from original due date (until Jul 5, 2023) to file.
No immediate impact on listing or trading of common stock on Nasdaq Global Select Market.
Lifecore states it is working diligently to complete and file the 10-Q as promptly as possible.

item 3.01 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

LIFECORE BIOMEDICAL, INC. DE received a nasdaq deficiency notice notice regarding late filing (rules 5250(c)(1)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: late filing
Rules: 5250(c)(1)

Exact text from the filing

January 11, 2023, Lifecore Biomedical, Inc., a Delaware corporation (the “Company”) received a notification letter (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, as a result of the Company’s delay in filing its Quarterly Report on Form 10-Q for the period ended November 27, 2022 (the “Form 10-Q”) with the Securities and Exchange Commission (the “SEC”), the Company is not in compliance with the requirements for continued listing under Nasdaq Listing Rule 5250(c)(1) (the “Listing Rule”). The notification letter has no immediat

View on SEC.gov

8 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

LIFECORE BIOMEDICAL, INC. DE filing history →

Source: SEC EDGAR

accession 0001005286-23-000027

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.